A federal grand jury issued a subpoena to Mount Sinai health system on Friday, demanding information about adolescent patients who received gender-related treatments. The subpoena represents the Trump administration's ongoing investigation into pediatric gender-affirming care across medical institutions. Mount Sinai confirmed the legal demand while stating its commitment to protecting patient confidentiality.

The hospital system emphasized it would only comply by providing de-identified information if legally required, citing its obligation to safeguard patient privacy. This marks a significant escalation in federal scrutiny of gender medicine practices, with prosecutors potentially examining treatment protocols and patient outcomes. Medical facilities nationwide have faced increasing pressure as Republican-led investigations expand beyond state-level restrictions.

Healthcare providers now face a difficult balancing act between legal compliance and patient trust. The subpoena could compel disclosure of sensitive medical records, raising concerns among advocacy groups about chilling effects on necessary care. Mount Sinai's cautious approach reflects broader industry tensions as institutions navigate political and legal crosscurrents.

The investigation signals intensified federal oversight of pediatric gender care, potentially influencing treatment protocols at major medical centers. For healthcare stocks and hospital systems, this creates regulatory uncertainty that investors will monitor closely through earnings seasons and policy developments.